Navigation Links
Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
Date:8/7/2008

in several clinical trials. If further studies document efficacy and safety, tesetaxel offers substantial opportunities to improve convenience, safety, and activity for patients who are currently receiving conventional taxanes.

G4544: A New Oral Drug for Skeletal Diseases

G4544 is the Company's proprietary small molecule that is intended to treat diseases associated with accelerated bone loss. G4544 contains the active ingredient in the Company's marketed product, Ganite(R). Genta completed a Phase 1 single-dose study of G4544, and the pharmacokinetics of G4544 were presented at the 2008 ASCO meeting. These data showed oral bioavailability in a range that may be effective for therapy of various bone diseases.

Financial Information

For the second quarter of 2008, the Company reported a net loss of $738.4 million, or $(20.10) per share, compared with a net loss of $8.2 million, or ($0.27) per share, for the second quarter of 2007. For the six months ended June 30, 2008, the Company reported a net loss of $748.0 million, or ($21.21) per share, compared with a net loss of $13.8 million, or ($0.48) per share, for the six months ended June 30, 2007. (All 2007 share and per-share data have been retroactively adjusted to account for the effect of a 1-for-6 reverse stock split on July 13, 2007.)

Net product sales of Ganite for the second quarter and six months ended June 30, 2008 of $0.1 million and $0.2 million, respectively, were virtually unchanged from the comparison periods one year ago. The Company has indicated it intends to seek a buyer for Ganite.

Research and development expenses were $4.5 million for the second quarter of 2008, compared with $4.1 million for second quarter of 2007. This increase was primarily due to higher expenses from the AGENDA clinical trial, partially offset by lower payroll costs. The Company reduced its workforce to conserve cash in both April and May 2008. Research and development expenses were $1
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Genta Announces Second Quarter 2008 Financial Results and Conference Call
2. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
3. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
4. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
5. Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
6. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
7. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
8. Dr. Elizabeth Brown Joins Argenta TEC
9. Syngenta To Build Major Global Biotech Research Center in Beijing, China
10. Genta Restructures Operations to Focus on Priority Initiatives
11. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 Tooth decay is an epidemic ... signs of the disease. The World Health Organization says that ... of adults have cavities. What are the long-term effects of ... a strong connection between the oral bacterial imbalance and serious ... so rampant, yet it is also 100% preventable? Answer: there ...
(Date:5/16/2013)... May 16, 2013 Oven Industries, Inc. ... controllers and temperature sensors since 1964. Expertly ... in industrial control system applications. As one ... includes a generic, control loop feedback system, which helps ... used to adjust a systematic process, using a control ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 Cambridge Healthtech ... from August 19-23, 2013 at the Renaissance Waterfront Hotel ... Summit provide a close-up look at the current strategies ... ensuring bottom-line quality. Leaders in the field will ... to produce biopharmaceuticals with greater specificity and efficiency. , ...
(Date:5/16/2013)... 2013  The registration deadline has been extended until ... 2013 National Conference, the premier conference for bioscience financial ... the Hilton San Diego Bayfront. "We ... and want to make sure as many people as ... Brandi Roberts , Chief Financial Officer of Mast ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3New PID Temperature Controllers Announced by Oven Industries Inc. 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4
... JCA-Mauvernay Award, LAUSANNE, Switzerland, October 29 ... specialist that,focuses on serious medical conditions and ... Mano with the 2008 JCA-Mauvernay,Award for their ... oncology.,The Awards were presented during the General ...
... Proximal Anastomosis System Received 510(k) Clearance from ... Drug Administration (FDA) -, - Development Progress Triggered $1M Milestone Payment from ... - Conference Call Today at 4:30 p.m. Eastern Time -, REDWOOD ... financial results and corporate progress,for its fiscal 2009 first quarter ended September ...
... COLUMBIA, Canada, Oct. 28 InNexus,Biotechnology Inc., (OTC ... a drug development company commercializing the next,generation of ... technology, announces that Jeff Morhet, CEO and Chairman, ... on October 30, 2008., Mr. Morhet,s thirty-minute ...
Cached Biology Technology:Japanese Cancer Association and Debiopharm Honour Japanese Research 2Japanese Cancer Association and Debiopharm Honour Japanese Research 3Cardica Announces Fiscal 2009 First Quarter Financial Results 2Cardica Announces Fiscal 2009 First Quarter Financial Results 3Cardica Announces Fiscal 2009 First Quarter Financial Results 4Cardica Announces Fiscal 2009 First Quarter Financial Results 5Cardica Announces Fiscal 2009 First Quarter Financial Results 6InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum 2
(Date:5/16/2013)... a gene involved in neurodegenerative disease also plays a ... clock. , In a study of the common ... keeps the clock responsible for sleeping and waking on ... the fruit fly,s sleep-wake cycle is disturbed, making waking ... , The discovery is particularly interesting because mutations ...
(Date:5/16/2013)... 16, 2013 The relationship between the heritable ... not been clear. Schizophrenia is commonly associated with ... are clues that reduced IQ may be linked ... reduced cognitive ability may precede the onset of ... in healthy relatives of people diagnosed with schizophrenia. ...
(Date:5/16/2013)... with ,scissor hand-like, claws in fossil records and has ... , The 505 million year old fossil called ... a distant ancestor of lobsters and scorpions, was named ... as Edward Scissorhands - a movie about an artificial ... for hands. , Kooteninchela deppi is ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 2Genetic risk for schizophrenia is connected to reduced IQ 2Actor Johnny Depp immortalized in ancient fossil find 2
... EMBARGOED UNTIL 1 P.M. EST 12/20/09 -- Boston ... future genome sequencing faster and cheaper by dramatically reducing ... time-consuming and error-prone step of DNA amplification. ... online edition of Nature Nanotechnology, a team ...
... Springer as the co-publisher of its Journal of ... quarterly journal will start publication at Springer with Volume ... 2001 will be available on Springer,s electronic platform ... and Environmental Statistics publishes papers of value to ...
... , SEATTLE, Dec. 18 Pacific Biometrics, Inc. ... provider of specialized central laboratory and contract research services, today ... voted upon at the Company,s Annual Meeting on December 14, ... change in the Company,s name to "Pacific Biomarkers, Inc." ...
Cached Biology News:Boston University reseachers develop faster, cheaper DNA sequencing method 2International Biometric Society co-publishes journal with Springer 2Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 2Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 3Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 4
MpV17 transgene, murine homolog, glomerulosclerosis...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and Silencer Pre-designed siRNAs, ...
... service provides the premium quality siRNAs you ... siRNAs can be readily ordered online by ... or by providing the sense and antisense ... Silencer Validated and Silencer ...
Biology Products: